Harvard Drug to launch $202 million facility via Credit Suisse, UBS

By Paul A. Harris

St. Louis, March 31 - Harvard Drug Group, LLC will hold an April 7 bank meeting for its $202 million senior secured credit facility, according to market sources.

Credit Suisse and UBS are leading the deal, which is comprised of a $160 million six-year term loan, a $22 million delayed-draw term loan and a $20 million revolver.

The price talk is Libor plus 450 basis points at 98 with a 2% Libor floor.

Proceeds will be used to help fund the acquisition of the Livonia, Mich.-based independent pharmaceutical distributor by Court Square Capital.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.